Compare BAK & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAK | WVE |
|---|---|---|
| Founded | 1972 | 2012 |
| Country | Brazil | Singapore |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | N/A | 2015 |
| Metric | BAK | WVE |
|---|---|---|
| Price | $2.84 | $7.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $4.40 | ★ $19.08 |
| AVG Volume (30 Days) | 1.2M | ★ 2.4M |
| Earning Date | 11-11-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,841,708,237.00 | $109,230,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.62 | $6.24 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 103.75 |
| 52 Week Low | $2.32 | $5.28 |
| 52 Week High | $5.26 | $16.38 |
| Indicator | BAK | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 48.99 |
| Support Level | $2.89 | $6.60 |
| Resistance Level | $3.05 | $7.78 |
| Average True Range (ATR) | 0.18 | 0.43 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 24.30 | 68.24 |
Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.